ARAY
Price
$2.19
Change
-$0.01 (-0.46%)
Updated
Sep 16, 03:01 PM (EDT)
44 days until earnings call
ZOM
Price
$0.13
Change
-$0.00 (-0.00%)
Updated
Sep 16, 10:14 AM (EDT)
56 days until earnings call
Ad is loading...

ARAY vs ZOM

Header iconARAY vs ZOM Comparison
Open Charts ARAY vs ZOMBanner chart's image
Accuray
Price$2.19
Change-$0.01 (-0.46%)
Volume$660
CapitalizationN/A
Zomedica
Price$0.13
Change-$0.00 (-0.00%)
Volume$128
CapitalizationN/A
View a ticker or compare two or three
ARAY vs ZOM Comparison Chart
Loading...
ARAY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZOM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ARAY vs. ZOM commentary
Sep 16, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARAY is a Buy and ZOM is a Buy.

COMPARISON
Comparison
Sep 16, 2024
Stock price -- (ARAY: $2.19 vs. ZOM: $0.13)
Brand notoriety: ARAY and ZOM are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ARAY: 56% vs. ZOM: 108%
Market capitalization -- ARAY: $244.95M vs. ZOM: $137.19M
ARAY [@Medical Specialties] is valued at $244.95M. ZOM’s [@Medical Specialties] market capitalization is $137.19M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARAY’s FA Score shows that 0 FA rating(s) are green whileZOM’s FA Score has 1 green FA rating(s).

  • ARAY’s FA Score: 0 green, 5 red.
  • ZOM’s FA Score: 1 green, 4 red.
According to our system of comparison, ARAY is a better buy in the long-term than ZOM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARAY’s TA Score shows that 6 TA indicator(s) are bullish while ZOM’s TA Score has 5 bullish TA indicator(s).

  • ARAY’s TA Score: 6 bullish, 4 bearish.
  • ZOM’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ARAY is a better buy in the short-term than ZOM.

Price Growth

ARAY (@Medical Specialties) experienced а +14.06% price change this week, while ZOM (@Medical Specialties) price change was +4.18% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +5.77%. For the same industry, the average monthly price growth was +7.52%, and the average quarterly price growth was +0.66%.

Reported Earning Dates

ARAY is expected to report earnings on Oct 30, 2024.

ZOM is expected to report earnings on Nov 11, 2024.

Industries' Descriptions

@Medical Specialties (+5.77% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARAY($245M) has a higher market cap than ZOM($137M). ARAY YTD gains are higher at: -22.615 vs. ZOM (-34.016). ARAY has higher annual earnings (EBITDA): 5.93M vs. ZOM (-11.94M). ZOM has more cash in the bank: 106M vs. ARAY (72.8M). ZOM has less debt than ARAY: ZOM (1.75M) vs ARAY (202M). ARAY has higher revenues than ZOM: ARAY (447M) vs ZOM (24M).
ARAYZOMARAY / ZOM
Capitalization245M137M179%
EBITDA5.93M-11.94M-50%
Gain YTD-22.615-34.01666%
P/E RatioN/AN/A-
Revenue447M24M1,863%
Total Cash72.8M106M69%
Total Debt202M1.75M11,530%
FUNDAMENTALS RATINGS
ARAY vs ZOM: Fundamental Ratings
ARAY
ZOM
OUTLOOK RATING
1..100
9654
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
29
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
3880
P/E GROWTH RATING
1..100
53100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZOM's Valuation (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for ARAY (81) in the Medical Specialties industry. This means that ZOM’s stock grew somewhat faster than ARAY’s over the last 12 months.

ZOM's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ARAY (100) in the Medical Specialties industry. This means that ZOM’s stock grew similarly to ARAY’s over the last 12 months.

ZOM's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as ARAY (97) in the Medical Specialties industry. This means that ZOM’s stock grew similarly to ARAY’s over the last 12 months.

ARAY's Price Growth Rating (38) in the Medical Specialties industry is somewhat better than the same rating for ZOM (80) in the Pharmaceuticals Major industry. This means that ARAY’s stock grew somewhat faster than ZOM’s over the last 12 months.

ARAY's P/E Growth Rating (53) in the Medical Specialties industry is somewhat better than the same rating for ZOM (100) in the Pharmaceuticals Major industry. This means that ARAY’s stock grew somewhat faster than ZOM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARAYZOM
RSI
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
88%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 5 days ago
84%
Declines
ODDS (%)
Bearish Trend 11 days ago
79%
Bearish Trend 13 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
81%
View a ticker or compare two or three
Ad is loading...
ARAY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZOM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCMUX38.280.50
+1.32%
Goldman Sachs Mid Cap Value R6
MINVX30.080.24
+0.80%
Madison Investors Y
BARIX112.910.87
+0.78%
Baron Asset Instl
LKBAX28.550.09
+0.32%
LKCM Balanced
RYAEX125.760.33
+0.26%
Rydex Europe 1.25x Strategy A

ARAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARAY has been loosely correlated with BRKR. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ARAY jumps, then BRKR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARAY
1D Price
Change %
ARAY100%
+3.30%
BRKR - ARAY
42%
Loosely correlated
+1.44%
XRAY - ARAY
42%
Loosely correlated
+3.51%
IQV - ARAY
40%
Loosely correlated
+0.13%
LH - ARAY
38%
Loosely correlated
+0.49%
VREX - ARAY
38%
Loosely correlated
+2.96%
More